Brokers Offer Predictions for FBRX FY2026 Earnings

Forte Biosciences, Inc. (NASDAQ:FBRX) – Brookline Capital Management issued their FY2026 earnings per share (EPS) estimates for Forte Biosciences in a report issued on Thursday, November 14th. Brookline Capital Management analyst K. Raja forecasts that the company will post earnings of ($2.17) per share for the year. The consensus estimate for Forte Biosciences’ current full-year earnings is ($22.50) per share. Brookline Capital Management also issued estimates for Forte Biosciences’ FY2027 earnings at ($1.66) EPS and FY2028 earnings at ($1.42) EPS.

Separately, Chardan Capital boosted their price target on Forte Biosciences from $3.00 to $64.00 and gave the company a “buy” rating in a research note on Friday.

Forte Biosciences Stock Up 4.7 %

Shares of FBRX opened at $5.84 on Monday. Forte Biosciences has a 12-month low of $4.11 and a 12-month high of $21.25. The firm has a market capitalization of $8.53 million, a price-to-earnings ratio of -0.36 and a beta of 0.04. The stock’s 50-day moving average price is $5.49 and its 200 day moving average price is $2.33.

Forte Biosciences Company Profile

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.